Trials / Terminated
TerminatedNCT02274233
Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
Multicenter, Open-label, Dose-escalation Study of SP-420 in Subjects With Transfusion-dependent β-Thalassemia
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Sideris Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety and amount of the study drug in the blood after increasing doses of SP-420. The study will be conducted in patients with β-thalassemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SP-420 |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2014-10-24
- Last updated
- 2015-09-29
Locations
7 sites across 5 countries: United States, Canada, Lebanon, Thailand, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT02274233. Inclusion in this directory is not an endorsement.